Purinergic P2Y Receptor Antagonists

"Purinergic P2Y Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes.

Descriptor ID	D058921
MeSH Number(s)	D27.505.519.625.725.400.200.200 D27.505.696.577.725.400.200.200
Concept/Terms	Purinergic P2Y Receptor Antagonists Purinergic P2Y Receptor Antagonists P2Y Purinoceptor Antagonists Antagonists, P2Y Purinoceptor Purinoceptor Antagonists, P2Y Purinergic P2Y1 Receptor Antagonists Purinergic P2Y1 Receptor Antagonists P2Y1 Purinoceptor Antagonists Antagonists, P2Y1 Purinoceptor Purinoceptor Antagonists, P2Y1 Purinergic P2Y2 Receptor Antagonists Purinergic P2Y2 Receptor Antagonists P2Y2 Purinoceptor Antagonists Antagonists, P2Y2 Purinoceptor Purinoceptor Antagonists, P2Y2 Adenosine Diphosphate Receptor Antagonists Adenosine Diphosphate Receptor Antagonists ADP Receptor Blockers Receptor Blockers, ADP ADP Receptor Antagonists Antagonists, ADP Receptor Receptor Antagonists, ADP Purinergic P2Y12 Receptor Antagonists Purinergic P2Y12 Receptor Antagonists P2Y12 Receptor Antagonists Antagonists, P2Y12 Receptor Receptor Antagonists, P2Y12 P2Y12 Purinoceptor Antagonists Antagonists, P2Y12 Purinoceptor Purinoceptor Antagonists, P2Y12

Below are MeSH descriptors whose meaning is more general than "Purinergic P2Y Receptor Antagonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Neurotransmitter Agents [D27.505.519.625]
Purinergic Agents [D27.505.519.625.725]
Purinergic Antagonists [D27.505.519.625.725.400]
Purinergic P2 Receptor Antagonists [D27.505.519.625.725.400.200]
Purinergic P2Y Receptor Antagonists [D27.505.519.625.725.400.200.200]
Physiological Effects of Drugs [D27.505.696]
Neurotransmitter Agents [D27.505.696.577]
Purinergic Agents [D27.505.696.577.725]
Purinergic Antagonists [D27.505.696.577.725.400]
Purinergic P2 Receptor Antagonists [D27.505.696.577.725.400.200]
Purinergic P2Y Receptor Antagonists [D27.505.696.577.725.400.200.200]

Below are MeSH descriptors whose meaning is related to "Purinergic P2Y Receptor Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Purinergic P2Y Receptor Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Purinergic P2Y Receptor Antagonists" by people in this website by year, and whether "Purinergic P2Y Receptor Antagonists" was a major or minor topic of these publications.

Bar chart showing 15 publications over 10 distinct years, with a maximum of 4 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2011	0	1	1
2012	1	0	1
2013	4	0	4
2014	1	0	1
2015	0	1	1
2016	1	0	1
2017	1	0	1
2018	3	0	3
2019	1	0	1
2021	0	1	1

Below are the most recent publications written about "Purinergic P2Y Receptor Antagonists" by people in Profiles.

Soueid AE, Kassas I, Rade J, Kakouros N. Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study. J Invasive Cardiol. 2021 04; 33(4):E263-E268.

View in: PubMed
Hariri E, Lessard D, Gore J, Rade J, Goldberg R. Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction? Cardiovasc Revasc Med. 2020 02; 21(2):182-188.

View in: PubMed
Frelinger AL, Gachet C, Mumford AD, Noris P, Mezzano D, Harrison P, Gresele P. Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH. J Thromb Haemost. 2018 11; 16(11):2341-2346.

View in: PubMed
Smolensky Koganov E, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, Przyklenk K, Frelinger AL. GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 09 28; 8(1):14529.

View in: PubMed
Gerrits AJ, Jakubowski JA, Michelson AD, Frelinger AL. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply. J Thromb Haemost. 2018 03; 16(3):607-608.

View in: PubMed
Gerrits AJ, Jakubowski JA, Sugidachi A, Michelson AD, Frelinger AL. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. J Thromb Haemost. 2017 05; 15(5):858-867.

View in: PubMed
Gremmel T, Yanachkov IB, Yanachkova MI, Wright GE, Wider J, Undyala VV, Michelson AD, Frelinger AL, Przyklenk K. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol. 2016 Mar; 36(3):501-9.

View in: PubMed
Yanachkov IB, Chang H, Yanachkova MI, Dix EJ, Berny-Lang MA, Gremmel T, Michelson AD, Wright GE, Frelinger AL. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem. 2016 Jan 01; 107:204-18.

View in: PubMed
Chang H, Yanachkov IB, Dix EJ, Yanachkova M, Li Y, Barnard MR, Wright GE, Michelson AD, Frelinger AL. Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'?-P? ,P4-dithio-P?,P?-chloromethylenetetraphosphate. PLoS One. 2014; 9(4):e94780.

View in: PubMed
Jakubowski JA, Zhou C, Jurcevic S, Winters KJ, Lachno DR, Frelinger AL, Gupta N, Howard J, Payne CD, Mant TG. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res. 2014 Feb; 133(2):190-5.

View in: PubMed

People

Explore

Similar Concepts

Top Journals